Retinal Physician – March 2021
March 2021 The Suprachoroidal Space: New Prospects for Gene Therapy Parisa Emami-Naeini and Glenn…
Related Articles
Artificial Intelligence and Augmented Intelligence in Ophthalmic Practice
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Improving Durability of Drugs in Wet AMD
Monthly or bimonthly anti-VEGF use poses significant time and cost burden due to the disease’s chronic nature and limited medication half-life. Further potential solutions to…
Episode 425 – April 2024 Retinal Physician Drug Delivery Issue
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Clinical Trial Update
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
New Product Applications
Harrow’s Iheezo, a topical ocular anesthetic, is the first FDA-approved use of chloroprocaine hydrochloride in the US ophthalmic market.
Coding Q&A
Retinal physicians face increasing pressure from government regulators and payors on various issues. To avoid regulatory scrutiny, it’s vital for practice administrators and owners to…
Upfront
Studies have shown upregulation of other VEGF subtypes when VEGF-A is blocked. This has led to several companies targeting VEGF-C and VEGF-D to improve outcomes…
Nesvategrast Fails to Meet Primary Efficacy Endpoint in DR:EAM Trial
OcuTerra will continue to analyze secondary endpoints to plan strategic alternatives.
LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
Atsena Therapeutics has announced that dosing has begun for the second cohort in LIGHTHOUSE, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201, a…